Amarin Corporation Securities Lawsuit Investigation

Our firm filed a class action lawsuit on behalf of Amarin Corporation (NASDAQ: AMRN) investors who purchased shares between September 24, 2018, and November 9, 2018.  On May 14, 2019, the federal judge overseeing this case appointed our law firm co-lead counsel in the case.  The appointed lead plaintiffs plan to file an amended complaint on behalf of a proposed class of investors by July 22, 2019.

Recover Your Amarin Losses. (NASDAQ: AMRN)

You may have a legal claim.  Speak to an attorney about your rights.


Amarin Corp. Stock Plunges 27% Following Publication of Vascepa Study

Last year, Amarin Corporation previewed to the public the results of a recently completed cardiovascular study relating to the drug Vascepa. The study would reportedly show a 25% relative risk reduction in certain cardiovascular events patients taking Vascepa, a drug developed by Amarin.  Amarin’s stock saw a 300% increase in value, from $2.99 to $12.40.

On November 10, 2018, scientists involved in the study presented more information about the study and its results. It has been reported that the additional information provided suggests the placebo used in the study, mineral oil, may have caused cardiovascular problems in patients taking it. Some believe that this meant that the study did not demonstrate that Vascepa lowered the risk of cardiovascular problems as previously reported. After this news was reported, Amarin stock decreased in value by 27% from $21.05 to $15.38 in about two days.

Gibbs Law Group's Financial Fraud Experience

Gibbs Law Group’s financial fraud and securities lawyers have more than two decades of experience prosecuting fraud. Our attorneys have successfully litigated against some of the largest companies in the United States, and we have recovered more than a billion dollars on our clients’ behalf.

We have fought some of the most complex cases brought under federal and state laws nationwide, and our attorneys have been recognized with numerous awards and honors for their accomplishments, including Top 100 Super Lawyers in Northern California, Top Plaintiff Lawyers in California, The Best Lawyers in America, and rated AV Preeminent (among the highest class of attorneys for professional ethics and legal skills).

titan of plaintiffs bar award
best law firm ranking
chambers USA leading firms award
daily journal top plaintiff lawyers award

Noteworthy Financial Fraud Cases

American Express Financial Advisors Securities Litigation$100 million cash settlement for clients alleging American Express steered them into under-performing “shelf space funds” to reap kickbacks
Chase Bank “Check Loan” Litigation$100 million settlement for consumers alleging Chase offered long-term fixed-rate loans, only to later more-than-double required payments
Peregrine Financial Group Customer LitigationSettlements worth $75 million for futures and commodities investors who lost millions in the collapse of Peregrine Financial Group, Inc.
NantHealthCourt-appointed Co-Lead Counsel in a securities class action alleging the company’s founder violated federal securities law and artificially inflated stock prices

Our Securities Attorneys

Jason Gibbs

Eric has served in leadership positions in a number of high profile, complex financial lawsuits. He has been recognized as a Daily Journal, among the Top 100 Super Lawyers in Northern California, and a Law360 MVP for Consumer Protection.

Dave Stein

David’s advocacy has generated major recoveries for consumers impacted by financial fraud. He was named to the Top 40 Under 40 by Daily Journal and a “Rising Star in Class Actions” by Law360.

Amanda Karl

Amanda represents employees, consumers, and sexual assault survivors in complex class actions. She also leads the firm’s Voting Rights Task Force.

AMRN stock losses?

Speak to a securities attorney to recover your money. Free, confidential consultations.